<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Project Inform &#187; HIV prevention</title>
	<atom:link href="http://www.projectinform.org/category/prevention-info/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.projectinform.org</link>
	<description>Information, inspiration and advocacy for people with HIV/AIDS and hepatitis C</description>
	<lastBuildDate>Wed, 11 Sep 2013 05:28:10 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.5.2</generator>
		<item>
		<title>Project Inform launches new educational videos on PrEP</title>
		<link>http://www.projectinform.org/news/project-inform-launches-new-educational-videos-on-prep/</link>
		<comments>http://www.projectinform.org/news/project-inform-launches-new-educational-videos-on-prep/#comments</comments>
		<pubDate>Wed, 11 Sep 2013 04:52:10 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[In the news]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=6975</guid>
		<description><![CDATA[Project Inform announced today the release of four new educational videos on the topic of PrEP, or Pre-Exposure Prophylaxis. PrEP is a new prevention tool that currently involves taking an HIV medication daily by an HIV-negative person to help prevent getting the virus. In July 2012,...<span class="readmore"><a href="http://www.projectinform.org/news/project-inform-launches-new-educational-videos-on-prep/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/news/project-inform-launches-new-educational-videos-on-prep/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>First rapid test approved to detect both HIV antigen and antibodies to HIV 1 and 2</title>
		<link>http://www.projectinform.org/hiv-news/first-rapid-test-approved-to-detect-both-hiv-antigen-and-antibodies-to-hiv-1-and-2/</link>
		<comments>http://www.projectinform.org/hiv-news/first-rapid-test-approved-to-detect-both-hiv-antigen-and-antibodies-to-hiv-1-and-2/#comments</comments>
		<pubDate>Fri, 09 Aug 2013 21:05:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[HIV care & treatment]]></category>
		<category><![CDATA[HIV prevention]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=6759</guid>
		<description><![CDATA[Improving the nation’s response to identifying the nearly 240,000 Americans who don’t know they have HIV and get them into care is a key goal of the National HIV/AIDS Strategy. The FDA has taken another step towards that goal by approving the first rapid test that...<span class="readmore"><a href="http://www.projectinform.org/hiv-news/first-rapid-test-approved-to-detect-both-hiv-antigen-and-antibodies-to-hiv-1-and-2/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/hiv-news/first-rapid-test-approved-to-detect-both-hiv-antigen-and-antibodies-to-hiv-1-and-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>USPSTF states most Americans should be tested for HIV</title>
		<link>http://www.projectinform.org/news/uspstf-states-most-americans-should-be-tested-for-hiv/</link>
		<comments>http://www.projectinform.org/news/uspstf-states-most-americans-should-be-tested-for-hiv/#comments</comments>
		<pubDate>Tue, 30 Apr 2013 00:05:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[In the news]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=6089</guid>
		<description><![CDATA[The US Preventive Services Task Force announced today that nearly all adolescents and adults in the United States should be screened for HIV infection. This final recommendation was based upon a review of current research on HIV screening as well as considering the information provided by...<span class="readmore"><a href="http://www.projectinform.org/news/uspstf-states-most-americans-should-be-tested-for-hiv/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/news/uspstf-states-most-americans-should-be-tested-for-hiv/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>HIV vaccine study HVTN 505 stopped early</title>
		<link>http://www.projectinform.org/news/hiv-vaccine-study-hvtn-505-stopped-early/</link>
		<comments>http://www.projectinform.org/news/hiv-vaccine-study-hvtn-505-stopped-early/#comments</comments>
		<pubDate>Mon, 29 Apr 2013 22:35:12 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[In the news]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=6085</guid>
		<description><![CDATA[The National Institute of Allergy and Infectious Diseases (NIAID) announced last week that it will stop the experimental vaccine injections in its HVTN 505 Phase IIb clinical study. An independent monitoring board found during an early review of the data (April 22) that the HIV vaccine...<span class="readmore"><a href="http://www.projectinform.org/news/hiv-vaccine-study-hvtn-505-stopped-early/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/news/hiv-vaccine-study-hvtn-505-stopped-early/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>CROI2013: Disappointing results of PrEP for women</title>
		<link>http://www.projectinform.org/prevention-info/croi2013-disappointing-results-of-prep-for-women/</link>
		<comments>http://www.projectinform.org/prevention-info/croi2013-disappointing-results-of-prep-for-women/#comments</comments>
		<pubDate>Tue, 12 Mar 2013 19:49:15 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[HIV prevention]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=5901</guid>
		<description><![CDATA[A second clinical trial studying pre-exposure prophylaxis (PrEP) in women in Africa has found that the intervention was no more helpful than a placebo in preventing new HIV infections, but that once again this was highly likely due to the fact that very few women were...<span class="readmore"><a href="http://www.projectinform.org/prevention-info/croi2013-disappointing-results-of-prep-for-women/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/prevention-info/croi2013-disappointing-results-of-prep-for-women/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Less than daily PrEP dosing may be OK for some</title>
		<link>http://www.projectinform.org/hiv-news/less-than-daily-prep-dosing-may-be-ok-for-some/</link>
		<comments>http://www.projectinform.org/hiv-news/less-than-daily-prep-dosing-may-be-ok-for-some/#comments</comments>
		<pubDate>Sat, 15 Sep 2012 00:03:10 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[HIV care & treatment]]></category>
		<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[daily dose]]></category>
		<category><![CDATA[dosing]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[pre-exposure prophylaxis]]></category>
		<category><![CDATA[PrEP]]></category>
		<category><![CDATA[prevention]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=4117</guid>
		<description><![CDATA[Gay and bisexual men and transwomen who take their pre-exposure prophylaxis (PrEP) medications as few as four times per week may still have strong protection against becoming infected with HIV, according to a study published in the September 12 issue of Science Translational Medicine. &#160; The...<span class="readmore"><a href="http://www.projectinform.org/hiv-news/less-than-daily-prep-dosing-may-be-ok-for-some/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/hiv-news/less-than-daily-prep-dosing-may-be-ok-for-some/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Disappointing News about Selzentry as PrEP</title>
		<link>http://www.projectinform.org/hiv-news/disappointing-news-about-selzentry-as-prep/</link>
		<comments>http://www.projectinform.org/hiv-news/disappointing-news-about-selzentry-as-prep/#comments</comments>
		<pubDate>Thu, 30 Aug 2012 07:35:31 +0000</pubDate>
		<dc:creator>David Evans</dc:creator>
				<category><![CDATA[HIV care & treatment]]></category>
		<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[macaques]]></category>
		<category><![CDATA[maraviroc]]></category>
		<category><![CDATA[pre-exposure prophylaxis]]></category>
		<category><![CDATA[PrEP]]></category>
		<category><![CDATA[Selzentry]]></category>
		<category><![CDATA[Truvada]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=3971</guid>
		<description><![CDATA[A presentation at the International AIDS Conference in Washington, D.C. in August has concerned HIV prevention activists, because researchers found that the antiretroviral (ARV) drug Selzentry (maraviroc) didn&#8217;t work as well as they hoped at preventing infection from the monkey version of HIV in macaque monkeys....<span class="readmore"><a href="http://www.projectinform.org/hiv-news/disappointing-news-about-selzentry-as-prep/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/hiv-news/disappointing-news-about-selzentry-as-prep/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>CDC Publishes New Interim Guidance on PrEP for Heterosexual Men and Women</title>
		<link>http://www.projectinform.org/hiv-news/cdc-publishes-new-interim-guidance-on-prep-for-heterosexual-men-and-women/</link>
		<comments>http://www.projectinform.org/hiv-news/cdc-publishes-new-interim-guidance-on-prep-for-heterosexual-men-and-women/#comments</comments>
		<pubDate>Fri, 10 Aug 2012 22:48:43 +0000</pubDate>
		<dc:creator>David Evans</dc:creator>
				<category><![CDATA[HIV care & treatment]]></category>
		<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[CDC]]></category>
		<category><![CDATA[emtricitabine]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[guidance]]></category>
		<category><![CDATA[heterosexual]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[PrEP]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[such as condoms]]></category>
		<category><![CDATA[tenofovir]]></category>
		<category><![CDATA[Truvada]]></category>
		<category><![CDATA[women]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=3891</guid>
		<description><![CDATA[The U.S. Centers for Disease Control and Prevention (CDC) in Atlanta has published a new interim guidance for health care professionals on the use of pre-exposure prophylaxis (PrEP) in heterosexual men and women. PrEP involves HIV-negative individuals taking the HIV drug Truvada (tenofovir + emtricitabine) to...<span class="readmore"><a href="http://www.projectinform.org/hiv-news/cdc-publishes-new-interim-guidance-on-prep-for-heterosexual-men-and-women/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/hiv-news/cdc-publishes-new-interim-guidance-on-prep-for-heterosexual-men-and-women/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>PI Applauds Positive FDA PrEP Decision: Urges Immediate Implementation Steps</title>
		<link>http://www.projectinform.org/hiv-news/pi-applauds-positive-fda-prep-decision-urges-immediate-implementation-steps/</link>
		<comments>http://www.projectinform.org/hiv-news/pi-applauds-positive-fda-prep-decision-urges-immediate-implementation-steps/#comments</comments>
		<pubDate>Sat, 12 May 2012 03:34:52 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[HIV care & treatment]]></category>
		<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[pre-exposure prophylaxis]]></category>
		<category><![CDATA[PrEP]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[Truvada]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=3540</guid>
		<description><![CDATA[Friday, May 11, 2012 PI Applauds Positive FDA PrEP Decision: Urges Immediate Implementation Steps San Francisco, CA &#8212; Project Inform cheered the decision Thursday by an advisory committee to the U.S. Food and Drug Administration (FDA) that the agency should approve tenofovir disoproxil fumarate/emtricitabine (TDF/FTC or...<span class="readmore"><a href="http://www.projectinform.org/hiv-news/pi-applauds-positive-fda-prep-decision-urges-immediate-implementation-steps/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/hiv-news/pi-applauds-positive-fda-prep-decision-urges-immediate-implementation-steps/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Project Inform urges FDA to approve use of HIV medication for prevention</title>
		<link>http://www.projectinform.org/hiv-news/leading-advocacy-group-urges-fda-to-approve-use-of-hiv-medication-for-prevention/</link>
		<comments>http://www.projectinform.org/hiv-news/leading-advocacy-group-urges-fda-to-approve-use-of-hiv-medication-for-prevention/#comments</comments>
		<pubDate>Wed, 09 May 2012 00:31:20 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[HIV care & treatment]]></category>
		<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[pre-exposure prophylaxis]]></category>
		<category><![CDATA[PrEP]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[Truvada]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=3526</guid>
		<description><![CDATA[Aggressive efforts to block new HIV infections are long overdue Noting that the United States has suffered 50,000 new cases of HIV infection a year for well over a decade, Project Inform today said that the time to implement bold new HIV prevention methodologies is long...<span class="readmore"><a href="http://www.projectinform.org/hiv-news/leading-advocacy-group-urges-fda-to-approve-use-of-hiv-medication-for-prevention/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/hiv-news/leading-advocacy-group-urges-fda-to-approve-use-of-hiv-medication-for-prevention/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Project Inform submits testimony supporting FDA approval of PrEP</title>
		<link>http://www.projectinform.org/hiv-news/project-inform-submits-testimony-supporting-fda-approval-of-prep/</link>
		<comments>http://www.projectinform.org/hiv-news/project-inform-submits-testimony-supporting-fda-approval-of-prep/#comments</comments>
		<pubDate>Fri, 27 Apr 2012 04:00:48 +0000</pubDate>
		<dc:creator>David Evans</dc:creator>
				<category><![CDATA[HIV care & treatment]]></category>
		<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[pre-exposure prophylaxis]]></category>
		<category><![CDATA[PrEP]]></category>
		<category><![CDATA[testimony]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=3481</guid>
		<description><![CDATA[On April 24, Project Inform submitted a written testimony to the U.S. Food and Drug Administration&#8217;s (FDA) Antiviral Advisory Committee in support of FDA approval of the antiviral drugs TDF/FTC (Truvada) to be offered to prevent HIV transmission among HIV-negative people. Though some groups have tried...<span class="readmore"><a href="http://www.projectinform.org/hiv-news/project-inform-submits-testimony-supporting-fda-approval-of-prep/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/hiv-news/project-inform-submits-testimony-supporting-fda-approval-of-prep/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Project Inform Lauds California HIV Research Program&#8217;s PrEP and TLC+ Studies</title>
		<link>http://www.projectinform.org/cure-advocacy/project-inform-lauds-california-hiv-research-programs-prep-and-tlc-studies/</link>
		<comments>http://www.projectinform.org/cure-advocacy/project-inform-lauds-california-hiv-research-programs-prep-and-tlc-studies/#comments</comments>
		<pubDate>Thu, 19 Apr 2012 04:02:54 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[HIV care & treatment]]></category>
		<category><![CDATA[HIV cure advocacy]]></category>
		<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[California]]></category>
		<category><![CDATA[cure PrEP]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[research]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=3459</guid>
		<description><![CDATA[Project Inform strongly applauds the announcement by the California HIV/AIDS Research Program (CHRP) of $11.8 million in funds to study two exceedingly promising new HIV prevention and care strategies: pre-exposure prophylaxis (PrEP) and testing and linkage to care plus treatment (TLC+). CHRP announced April 17 that...<span class="readmore"><a href="http://www.projectinform.org/cure-advocacy/project-inform-lauds-california-hiv-research-programs-prep-and-tlc-studies/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/cure-advocacy/project-inform-lauds-california-hiv-research-programs-prep-and-tlc-studies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Project Inform requests quick FDA review of Truvada for prevention</title>
		<link>http://www.projectinform.org/hiv-news/fda-review-of-truvada-prep/</link>
		<comments>http://www.projectinform.org/hiv-news/fda-review-of-truvada-prep/#comments</comments>
		<pubDate>Tue, 07 Feb 2012 06:15:20 +0000</pubDate>
		<dc:creator>semerson</dc:creator>
				<category><![CDATA[HIV care & treatment]]></category>
		<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[pre-exposure]]></category>
		<category><![CDATA[PrEP]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[prophylaxis]]></category>
		<category><![CDATA[Truvada]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=3249</guid>
		<description><![CDATA[On January 25, Project Inform (PI), along with 25 other top HIV advocacy groups, sent a letter to the U.S. Food and Drug Administration (FDA) asking them to give a speedy review to Gilead Science&#8217;s application for the anti-HIV medication Truvada (tenofovir and emtricitabine) for pre-exposure...<span class="readmore"><a href="http://www.projectinform.org/hiv-news/fda-review-of-truvada-prep/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/hiv-news/fda-review-of-truvada-prep/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>13 Leading AIDS Orgs Call on FDA to Move on PrEP for MSMs and Transgenders</title>
		<link>http://www.projectinform.org/hiv-news/13-leading-aids-orgs-call-on-fda-to-move-on-prep-for-msm/</link>
		<comments>http://www.projectinform.org/hiv-news/13-leading-aids-orgs-call-on-fda-to-move-on-prep-for-msm/#comments</comments>
		<pubDate>Wed, 19 Oct 2011 02:29:37 +0000</pubDate>
		<dc:creator>David Evans</dc:creator>
				<category><![CDATA[HIV care & treatment]]></category>
		<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[pre-exposure]]></category>
		<category><![CDATA[PrEP]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[prophylaxis]]></category>
		<category><![CDATA[Truvada]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=3111</guid>
		<description><![CDATA[Thirteen leading AIDS organizations are calling on Gilead Sciences and the U.S. Food and Drug Administration (FDA) to move more quickly on plans to evaluate the use of the HIV drug Truvada (tenofovir and emtricitabine) in HIV-negative men who have sex with men (MSM) and transgender...<span class="readmore"><a href="http://www.projectinform.org/hiv-news/13-leading-aids-orgs-call-on-fda-to-move-on-prep-for-msm/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/hiv-news/13-leading-aids-orgs-call-on-fda-to-move-on-prep-for-msm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Welcome back the 1980s: An opinion piece on PrEP by David Evans</title>
		<link>http://www.projectinform.org/hiv-news/welcome-back-the-1980s/</link>
		<comments>http://www.projectinform.org/hiv-news/welcome-back-the-1980s/#comments</comments>
		<pubDate>Thu, 21 Jul 2011 03:11:21 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[HIV care & treatment]]></category>
		<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[pre-exposure]]></category>
		<category><![CDATA[PrEP]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[prophylaxis]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=2499</guid>
		<description><![CDATA[Reprinted from Poz.com (link below) I read Regan Hofmann&#8217;s blog-post last week titled &#8220;Not Drinking the PrEP Kool-AIDS&#8221; with a mixture of dread (would I be accused of being an irresponsible PrEP cheerleader?) and a growing sense of dÃ©jÃ  vu. By the end of the piece...<span class="readmore"><a href="http://www.projectinform.org/hiv-news/welcome-back-the-1980s/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/hiv-news/welcome-back-the-1980s/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Project Inform urges government action following the positive results of two PrEP studies in heterosexual men and women</title>
		<link>http://www.projectinform.org/hiv-news/project-inform-urges-government-action-following-the-positive-results-of-two-prep-studies-in-heterosexual-men-and-women/</link>
		<comments>http://www.projectinform.org/hiv-news/project-inform-urges-government-action-following-the-positive-results-of-two-prep-studies-in-heterosexual-men-and-women/#comments</comments>
		<pubDate>Fri, 15 Jul 2011 09:15:53 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[HIV care & treatment]]></category>
		<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[clinical]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[pre-exposure]]></category>
		<category><![CDATA[PrEP]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[prophylaxis]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[results]]></category>
		<category><![CDATA[studies]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[trial]]></category>
		<category><![CDATA[trials]]></category>
		<category><![CDATA[Truvada]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=2272</guid>
		<description><![CDATA[San Francisco, CA &#8212; Two new studies of pre-exposure prophylaxis (PrEP) in heterosexuals in Africa have demonstrated that the antiretroviral (ARV) Viread (tenofovir) or Truvada (tenofovir plus emtracitabine), taken by HIV-negative people, substantially reduces the number of new HIV infections. &#8220;The success of these new studies&#8212;when...<span class="readmore"><a href="http://www.projectinform.org/hiv-news/project-inform-urges-government-action-following-the-positive-results-of-two-prep-studies-in-heterosexual-men-and-women/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/hiv-news/project-inform-urges-government-action-following-the-positive-results-of-two-prep-studies-in-heterosexual-men-and-women/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ready to launch: ADAPT study looks at intermittent dosing of PrEP</title>
		<link>http://www.projectinform.org/hiv-news/ready-to-launch-adapt-study-of-pre/</link>
		<comments>http://www.projectinform.org/hiv-news/ready-to-launch-adapt-study-of-pre/#comments</comments>
		<pubDate>Thu, 07 Jul 2011 09:31:56 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[HIV care & treatment]]></category>
		<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[ADAPT]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[clinical]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[pre-exposure]]></category>
		<category><![CDATA[PrEP]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[prophylaxis]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[results]]></category>
		<category><![CDATA[studies]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[trial]]></category>
		<category><![CDATA[trials]]></category>
		<category><![CDATA[Truvada]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=2296</guid>
		<description><![CDATA[by Meredith Mazzotta, Center for Global Health Policy Investigators at the HIV Prevention Trials Network (HPTN) Annual Meeting Monday received an update on a study looking to ease the pill burden on those wishing to benefit from pre-exposure prophylaxis (PrEP). Inspired by studies of non-human primates...<span class="readmore"><a href="http://www.projectinform.org/hiv-news/ready-to-launch-adapt-study-of-pre/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/hiv-news/ready-to-launch-adapt-study-of-pre/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Project Inform releases report and recommendations on the financing of PrEP</title>
		<link>http://www.projectinform.org/hiv-news/project-inform-releases-prep-financing-report/</link>
		<comments>http://www.projectinform.org/hiv-news/project-inform-releases-prep-financing-report/#comments</comments>
		<pubDate>Fri, 17 Jun 2011 09:29:49 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[HIV care & treatment]]></category>
		<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[clinical]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[pre-exposure]]></category>
		<category><![CDATA[PrEP]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[prophylaxis]]></category>
		<category><![CDATA[recommendations]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[results]]></category>
		<category><![CDATA[studies]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[trial]]></category>
		<category><![CDATA[trials]]></category>
		<category><![CDATA[Truvada]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=2292</guid>
		<description><![CDATA[Read the REPORT. The iPrEx study considered whether taking the drug Truvada on a daily basis, in combination with safe sex counseling, could prevent gay and bisexual men from becoming infected with HIV.Â  In November, the study reported that Pre-Exposure Prophylaxis, or PrEP, could be as...<span class="readmore"><a href="http://www.projectinform.org/hiv-news/project-inform-releases-prep-financing-report/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/hiv-news/project-inform-releases-prep-financing-report/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Disappointing early results halt women&#8217;s PrEP study</title>
		<link>http://www.projectinform.org/hiv-news/disappointing-early-results-halt-womens-prep-study/</link>
		<comments>http://www.projectinform.org/hiv-news/disappointing-early-results-halt-womens-prep-study/#comments</comments>
		<pubDate>Thu, 12 May 2011 09:19:10 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[HIV care & treatment]]></category>
		<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[clinical]]></category>
		<category><![CDATA[FEM-PrEP]]></category>
		<category><![CDATA[halted]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[pre-exposure]]></category>
		<category><![CDATA[PrEP]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[prophylaxis]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[results]]></category>
		<category><![CDATA[stopped]]></category>
		<category><![CDATA[studies]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[trial]]></category>
		<category><![CDATA[trials]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=1173</guid>
		<description><![CDATA[April 22, 2011 On April 18, 2011, researchers stopped a study that used a daily pill to prevent HIV infection in heterosexual women.Â Early results from the study, called FEM PrEP, revealed it could not show that Truvada would work in this study population. The researchers cautioned...<span class="readmore"><a href="http://www.projectinform.org/hiv-news/disappointing-early-results-halt-womens-prep-study/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/hiv-news/disappointing-early-results-halt-womens-prep-study/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Momentum on PrEP should continue despite results of FEM-PrEP study</title>
		<link>http://www.projectinform.org/hiv-news/momentum-on-prep-should-continue-despite-fem-prep-study/</link>
		<comments>http://www.projectinform.org/hiv-news/momentum-on-prep-should-continue-despite-fem-prep-study/#comments</comments>
		<pubDate>Wed, 20 Apr 2011 09:16:20 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[HIV care & treatment]]></category>
		<category><![CDATA[HIV prevention]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[clinical]]></category>
		<category><![CDATA[FEM-PrEP]]></category>
		<category><![CDATA[halted]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[pre-exposure]]></category>
		<category><![CDATA[PrEP]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[prophylaxis]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[results]]></category>
		<category><![CDATA[stopped]]></category>
		<category><![CDATA[studies]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[trial]]></category>
		<category><![CDATA[trials]]></category>

		<guid isPermaLink="false">http://www.projectinform.org/?p=1168</guid>
		<description><![CDATA[April 20, 2011 The iPrEx study, conducted amongÂ  2,499 gay and bisexual men and female transgenders at high risk for HIV-infection in the US, South Africa, South America and Thailand, reported extremely hopeful results about the effectiveness of taking theÂ  antiretroviral Truvada daily in combination with...<span class="readmore"><a href="http://www.projectinform.org/hiv-news/momentum-on-prep-should-continue-despite-fem-prep-study/">Read More</a></span>]]></description>
		<wfw:commentRss>http://www.projectinform.org/hiv-news/momentum-on-prep-should-continue-despite-fem-prep-study/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>